104472-68-6
Chemical Structure
Typhaneoside
- CAS. Nr.: 104472-68-6
- Formula:C34H42O20
- Molecular Weight:770.69
IUPAC Name: 3-(((2S,3R,4S,5S,6R)-4,5-dihydroxy-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one
InChIKey: POMAQDQEVHXLGT-QDYYQVSOSA-N
SMILES: O=C1C(O[C@H](O[C@H](CO[C@H](O[C@@H](C)[C@H](O)[C@H]2O)[C@@H]2O)[C@@H](O)[C@@H]3O)[C@@H]3O[C@@](O[C@@H](C)[C@H](O)[C@H]4O)([H])[C@@H]4O)=C(C5=CC(OC)=C(O)C=C5)OC6=CC(O)=CC(O)=C16
Biological Activity: Typhaneoside is an orally active activator of PI3K/Akt/mTOR and farnesoid X receptor. Typhaneoside promotes the activation of AMPK and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, cell cycle arrest at the G2/M phase, and reduces cancer cell viability. Typhaneoside improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside can be used in research related to heart failure after myocardial infarction, acute myeloid leukemia, non-alcoholic fatty liver disease and neurological disorders[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Typhaneoside | 99.74% | Typhaneoside is an orally active activator of PI3K/Akt/mTOR and farnesoid X receptor. Typhaneoside promotes the activation of AMPK and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, cell cycle arrest at the G2/M phase, and reduces cancer cell viability. Typhaneoside improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside can be used in research related to heart failure after myocardial infarction, acute myeloid leukemia, non-alcoholic fatty liver disease and neurological disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Typhaneoside (Standard) | ≥98% | Typhaneoside (Standard) is the analytical standard of Typhaneoside. This product is intended for research and analytical applications. Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zhang X, et al. Effect of typhaneoside on ventricular remodeling and regulation of PI3K/Akt/mTOR pathway. Wirkung von Typhaneosid auf ventrikuläres Remodeling und Regulierung des PI3K/Akt/mTOR-Signalwegs. Herz. 2020;45(Suppl 1):113-122. [Content Brief]
- [2]. Zhu HY, et al. Typhaneoside prevents acute myeloid leukemia (AML) through suppressing proliferation and inducing ferroptosis associated with autophagy. Biochem Biophys Res Commun. 2019;516(4):1265-1271. [Content Brief]
- [3]. Zheng Y, et al. Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro. Biomed Pharmacother. 2023;164:114957. [Content Brief]
- [4]. Chiu KM, et al. Typhaneoside Suppresses Glutamate Release Through Inhibition of Voltage-Dependent Calcium Entry in Rat Cerebrocortical Nerve Terminals. Chem Res Toxicol. 2021;34(5):1286-1295. [Content Brief]
Keywords
